respectively Apnimed, Inc. Logo (PRNewsfoto/Apnimed, Inc.) "With the first patient dosed in the Phase 2A RESTEADY trial, both Apnimed and SASS have reached an important milestone – the ...

US-based Apnimed has dosed the first subject in the multi-centre Phase IIA RESTEADY trial of SASS-001, an oral drug combo for sleep apnoea with a central component. SASS-001 is a combination of ...

CAMBRIDGE, Mass., March 11, 2025 /PRNewswire/ -- Apnimed, Inc., a pharmaceutical company focused on discovering, developing, and commercializing first-in-class oral therapies for the neuromuscular ...

Apnimed will also be hosting 1x1 investor meetings on Monday, April 7, 2025, and Tuesday April 8, 2025. Investors interested in meeting with Apnimed should contact their Needham representative ...

"Today's announcement represents the combined efforts of the Apnimed and Shionogi teams, highlighting their respective strengths in sleep medicine drug development and drug discovery." RESTEADY is ...

April 7, 2025 /PRNewswire/ -- Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive ...